Ptc Therapeutics (PTCT) Cash from Investing Activities (2012 - 2026)

Ptc Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$93.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 49.16% year-over-year to -$93.7 million; the TTM figure through Mar 2026 stood at -$771.4 million (down 2955.38% YoY), while the FY2025 annual figure was -$862.0 million, down 2050.98% from the prior year.
• Cash from Investing Activities was -$93.7 million for Q1 2026 at Ptc Therapeutics, down from $34.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $267.7 million in Q4 2024 to a low of -$422.0 million in Q2 2025.
• Historically, Cash from Investing Activities has averaged -$46.9 million across 5 years, with a median of -$29.6 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities jumped 383.54% in 2024, then slumped 578.67% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $32.4 million in 2022, then tumbled by 391.06% to -$94.4 million in 2023, then surged by 383.54% to $267.7 million in 2024, then slumped by 87.3% to $34.0 million in 2025, then tumbled by 375.63% to -$93.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$93.7 million (Q1 2026), $34.0 million (Q4 2025), and -$289.6 million (Q3 2025), per Business Quant data.